BriaCell Therapeutics Corp. (BCTX)
3.575
0.00 (0.00%)
USD |
NASDAQ |
Sep 08, 16:00
BriaCell Therapeutics Enterprise Value : 2.467M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 2.467M |
| September 04, 2026 | 2.431M |
| September 03, 2026 | 2.141M |
| September 02, 2026 | 2.431M |
| September 01, 2026 | 2.866M |
| August 31, 2026 | 2.576M |
| August 28, 2026 | 3.591M |
| August 27, 2026 | 3.446M |
| August 26, 2026 | 5.766M |
| August 25, 2026 | 3.881M |
| August 24, 2026 | 1.633M |
| August 21, 2026 | 6.056M |
| August 20, 2026 | 5.041M |
| August 19, 2026 | 5.258M |
| August 18, 2026 | 2.141M |
| August 17, 2026 | 1.126M |
| August 14, 2026 | 1.488M |
| August 13, 2026 | 1.488M |
| August 12, 2026 | 1.271M |
| August 11, 2026 | 1.561M |
| August 10, 2026 | 1.126M |
| August 07, 2026 | 2.938M |
| August 06, 2026 | 1.561M |
| August 05, 2026 | 1.923M |
| August 04, 2026 | 0.9807M |
| Date | Value |
|---|---|
| August 03, 2026 | 0.9082M |
| July 31, 2026 | 1.488M |
| July 30, 2026 | 2.866M |
| July 29, 2026 | 1.198M |
| July 28, 2026 | 1.706M |
| July 27, 2026 | 2.286M |
| July 24, 2026 | 2.503M |
| July 23, 2026 | 3.518M |
| July 22, 2026 | 2.648M |
| July 21, 2026 | 3.736M |
| July 20, 2026 | 2.975M |
| July 17, 2026 | 3.591M |
| July 16, 2026 | 4.461M |
| July 15, 2026 | 5.114M |
| July 14, 2026 | 3.373M |
| July 13, 2026 | 3.736M |
| July 10, 2026 | 5.114M |
| July 09, 2026 | 2.938M |
| July 08, 2026 | 3.373M |
| July 07, 2026 | 1.851M |
| July 06, 2026 | 1.923M |
| July 02, 2026 | 0.1831M |
| July 01, 2026 | 1.706M |
| June 30, 2026 | 0.0381M |
| June 29, 2026 | -0.977M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Edesa Biotech, Inc. | 43.64M |
| ProMIS Neurosciences, Inc. | 58.90M |
| Arrowhead Pharmaceuticals, Inc. | 11.79B |
| Oncolytics Biotech, Inc. | 96.67M |
| Sangamo Therapeutics, Inc. | 58.40M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -7.237M |
| Total Expenses (Quarterly) | 7.164M |
| EPS Diluted (Quarterly) | -0.9881 |
| Earnings Yield | -341.6% |
| Normalized Earnings Yield | -348.64 |